Regulating lipid levels via the zmax1 or hbm gene

Details for Australian Patent Application No. 2001269712 (hide)

Owner Creighton University Oscient Pharmaceuticals Corporation

Inventors Little, Randall D.; Recker, Robert R.; Carulli, John P.; Johnson, Mark L

Agent Blake Dawson Waldron Patent Services

Pub. Number AU-B-2001269712

PCT Pub. Number WO01/92891

Priority 09/578,900 26.05.00 US

Filing date 25 May 2001

Wipo publication date 11 December 2001

Acceptance publication date 22 February 2007

International Classifications

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

A61K 31/095 (2006.01) - Sulfur, selenium or tellurium compounds, e.g. thiols

A61K 31/192 (2006.01)

A61K 31/22 (2006.01)

A61K 31/351 (2006.01) - not condensed with another ring

A61K 31/366 (2006.01) - having six-membered rings, e.g. delta-lactones

A61K 31/455 (2006.01) - Nicotinic acid, i.e. niacin

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61K 31/785 (2006.01)

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12Q 1/02 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving viable micro-organisms

G01N 33/15 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Medicinal preparations

G01N 33/53 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Immunoassay

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

9 October 2003 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 01 Sep 2003

1 June 2006 Change of Name(s) of Applicant(s), Section 104

  Creighton University; Genome Therapeutics Corporation The name of the applicant has been changed to Creighton University; Oscient Pharmaceuticals Corporation 2003

22 February 2007 Application Accepted

  Published as AU-B-2001269712

21 June 2007 Standard Patent Sealed

22 December 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001269713-Novel proteins and nucleic acids encoding same

2001269711